YDO1 Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Madrigal Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$293.80 |
| 52 Week High | US$336.00 |
| 52 Week Low | US$155.10 |
| Beta | -0.40 |
| 1 Month Change | -11.37% |
| 3 Month Change | 46.17% |
| 1 Year Change | 37.87% |
| 3 Year Change | 284.05% |
| 5 Year Change | 251.44% |
| Change since IPO | 112,467.05% |
Recent News & Updates
Recent updates
Shareholder Returns
| YDO1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 2.0% | -2.9% | -2.6% |
| 1Y | 37.9% | -14.7% | 6.9% |
Return vs Industry: YDO1 exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: YDO1 exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| YDO1 volatility | |
|---|---|
| YDO1 Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: YDO1's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: YDO1's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 376 | Bill Sibold | www.madrigalpharma.com |
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. Fundamentals Summary
| YDO1 fundamental statistics | |
|---|---|
| Market cap | €6.45b |
| Earnings (TTM) | -€497.09m |
| Revenue (TTM) | €73.62m |
87.6x
P/S Ratio-13.0x
P/E RatioIs YDO1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| YDO1 income statement (TTM) | |
|---|---|
| Revenue | US$76.81m |
| Cost of Revenue | US$2.79m |
| Gross Profit | US$74.03m |
| Other Expenses | US$592.70m |
| Earnings | -US$518.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -23.78 |
| Gross Margin | 96.37% |
| Net Profit Margin | -675.24% |
| Debt/Equity Ratio | 15.1% |
How did YDO1 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 12:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Madrigal Pharmaceuticals, Inc. is covered by 22 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Jason Zemansky | BofA Global Research |
| Alexandria Hammond | BofA Global Research |